Sponsors and CROs no longer hire clinical research associates (CRAs) the way they did a decade ago. Trials have spread out of any single home country, monitoring has shifted partly remote, and the buyer's question is now structurally different: not "who is the best CRA in our city," but "where does the right CRA live, and how do we employ them legally without standing up an entity for one hire."
This guide is the operating answer. It maps where CRAs actually live in 2026, what they cost loaded, how to choose between contractor, Employer of Record (EOR), and local entity, and what a clean 30/60/90-day rollout looks like. It is the role-level companion to our hub on why medical companies use EOR.
Why CRA hiring has shifted out of one-country models
Three forces broke the single-country CRA model.
Trial geography moved. ClinicalTrials.gov registrations span 220+ countries, and sponsors have meaningfully diversified study footprint away from China since 2022. Poland, India, the Czech Republic, Spain, and Brazil are now routine sites for Phase II and III work that a decade ago would have been concentrated in the US, Western Europe, and China. The CRA, who must monitor sites in person and remotely, has to live near where studies enroll.
Regulators legitimized remote and decentralized monitoring. The FDA's 2023 draft guidance on decentralized clinical trials and the EMA's recommendation paper on decentralized elements both formalized hybrid monitoring as acceptable when adequately controlled. CRAs can now legitimately be placed in a country adjacent to the site rather than always co-located.
ICH-GCP E6(R3) raised the bar on oversight, not co-location. The ICH-GCP E6(R3) guideline, adopted in early 2025, emphasizes risk-proportionate monitoring and sponsor oversight. Sponsors are accountable for quality regardless of where the CRA is employed, which makes the employment vehicle (contractor, EOR, entity) a compliance question, not just an HR one.
The combined effect: CRA hiring is now a global sourcing problem. Sponsors and CROs that solve it well hire from talent hubs that match their trial map, on locally compliant employment contracts, without paying nine months of entity-setup time per country.
Where CRAs actually live and what they cost
Loaded cost (gross salary plus statutory employer contributions) is the right way to compare. Statutory rates vary materially. Use country statistical agencies and OECD as the source of truth.
EU hubs: Poland, Portugal, Spain, Czechia
These four jurisdictions are the most common European CRA hires Borderless and other EORs see.
- Poland. Long-established CRO bench (Parexel, IQVIA, ICON, and Medpace all run substantial Polish operations). Polish employer social contributions run roughly 19.21% to 22.41% of gross salary on top of base, per ZUS contribution rates.
- Portugal. Lower salary point than Spain, English-fluent, English-language clinical training pipelines through Lisbon and Porto universities. Employer Social Security contribution sits at 23.75% of gross.
- Spain. Larger pool than Portugal; the Spanish Social Security employer rate totals roughly 30% to 32% of gross depending on contingencies. Common for HEOR-adjacent CRAs and senior monitors.
- Czechia. Mid-cost EU bench with strong Phase I to III experience. Czech employer social and health contributions total 33.8% of gross.
Loaded cost, as a working planning ratio: assume 1.20× to 1.35× gross salary for these four countries before benefits top-ups. The OECD Taxing Wages dataset is the cleanest cross-country comparison for confirming employer-side wedge.
APAC: India and Philippines
India remains the largest single CRA market outside the US. Major CROs disclose substantial India headcount in public filings; IQVIA's 2024 10-K lists India as one of its largest delivery footprints, and ICON plc's annual report similarly identifies India as a strategic delivery location. Indian statutory employer contributions (EPF + ESI + gratuity reserve) typically add 13% to 15% on top of base, per the EPFO contribution schedule.
The Philippines is a smaller but growing center, especially for English-language pharmacovigilance-adjacent CRA work. Philippine employer SSS, PhilHealth, and Pag-IBIG contributions add roughly 10% to 13% of gross.
A planning loaded-cost stack for an India-based CRA II in 2026, before discretionary benefits:
This is a planning range, not a quote. Country-specific finance review is required.
LATAM: Brazil and Mexico
Brazil is the largest LATAM clinical-trial market and the natural CRA hub for Portuguese-language sites. Brazilian employer contributions, including INSS, FGTS, and the so-called "Sistema S," cumulatively add 28% to 37% on top of gross depending on industry classification, before 13th-month and vacation accruals.
Mexico anchors Spanish-language CRA hiring across the region. IMSS and Infonavit employer contributions total roughly 25% to 30% of gross. The Mexican CRA bench is smaller than Brazil's but has grown notably as sponsors diversify LATAM site selection.
Contractor vs EOR vs local entity for CRA hiring
Three vehicles, three different risk profiles.
1099 / independent contractor. Same-day setup. Pay-per-invoice. The honest constraint: most CRAs do not meet the legal definition of an independent contractor. They follow a sponsor-defined monitoring plan, work fixed hours, use sponsor systems, and represent the sponsor at sites. The US Department of Labor's economic-realities test, as codified in the 2024 final rule at 29 CFR Part 795, treats that pattern as employment. Healthcare-staffing misclassification has been actively enforced; see the 2022 DOL consent judgment recovering $9.3 million for misclassified home health aides. Most non-US jurisdictions apply parallel tests. Contractor status for a full-time CRA is rarely defensible.
Employer of Record. A third party legally employs the CRA in their home country, on a locally compliant contract, while the sponsor or CRO directs day-to-day work. The time to first hire can be anywhere from days to two weeks. The CRA gets statutory benefits, the sponsor gets clean payroll and termination compliance, and there is no entity to wind down if the trial map changes.
Local entity. Best when headcount in a country crosses roughly 10 to 20 employees and the sponsor expects multi-year presence. Setup typically takes three to nine months and runs $15K to $50K+ before recurring legal, accounting, and payroll costs. For a single CRA in Czechia, this is overbuilt. For a 30-person Polish operations hub, it is right-sized.
A useful sequencing rule: start in a new country via EOR, migrate to a local entity once the team is stable above the cost crossover. Many CROs and sponsors run this exact path.
What to check on a CRA's credentialing and country-of-residence status
EOR removes the employment-law question. It does not remove sponsor diligence on the CRA themselves.
- GCP training currency. Confirm TransCelerate-recognized GCP training is current. Most sponsors require refresh every two to three years.
- Therapeutic-area experience documentation. CV evidence of monitoring visits per protocol type, plus references from prior sponsor or CRO relationships.
- Country of residence and right to work. The CRA's tax-residency country determines which entity employs them. A CRA "based in" Lisbon but tax-resident in Brazil is a different legal hire than one tax-resident in Portugal. Get this in writing before contracting.
- Site-monitoring travel reach. Confirm passport, Schengen residency or visa status, and any country-entry restrictions for the trial map.
- Conflicts and prior-employment non-competes. Especially relevant for ex-CRO hires moving to sponsors.
ICH-GCP E6(R3) keeps sponsor responsibility for monitoring quality with the sponsor regardless of who is the legal employer. The EOR does not absorb that responsibility.
The monitoring-visit travel and expense reality
A working CRA spends real time on the road even in a hybrid-monitoring world. Sponsors and CROs that under-budget travel pay for it later in attrition.
Plan for:
- 8 to 14 site visits per CRA per year for Phase II and III, lower for purely remote-monitored protocols.
- Per-visit travel envelope of $400 to $2,000 in EU intra-region, higher for cross-region.
- Reimbursement compliance under local rules. The EOR will pass through expenses, but the sponsor must define the policy. Some countries (Germany, France) treat per-diems and mileage on specific statutory schedules.
- Working-time and rest rules. EU Working Time Directive limits and national variants apply to travel time in some jurisdictions. Worth a country-by-country review before a heavy-monitoring protocol launches.
A travel and expense policy attached to the employment contract avoids most of the recurring friction.
30/60/90-day setup through an EOR
What a clean rollout looks like for a sponsor or CRO hiring its first international CRAs.
- Days 1 to 7. Provider verification (entities held in target countries, GCP-relevant data-handling, sanctions screening). MSA signed. Country and role list locked. Onboarding portal access.
- Days 7 to 21. First country live. Locally compliant employment contract issued in the CRA's language. Background and credential checks (GCP training, prior-employment, where-applicable license verification). Statutory and supplemental benefits enrolled. Trial-system access (CTMS, eTMF, EDC) provisioned by the sponsor.
- Days 21 to 45. First payroll cycle runs. HRIS sync confirmed (Workday, BambooHR, or similar). Expense and time-off processes verified against the monitoring-visit travel policy. Equity treatment confirmed if applicable.
- Days 45 to 90. Second and third countries onboarded on the same template. Quarterly compliance review scheduled. Country-specific anomalies reviewed (Brazilian 13th-month and FGTS, Polish PIT-2 elections, Indian gratuity accrual, Spanish fixed-term restrictions under the 2022 labor reform).
Sponsors who treat the first 90 days as a structured rollout, not a one-off hire, get materially better results from any EOR.
Honest limits: what an EOR does not solve for CRA hiring
The most useful thing this article can say is what EOR does not do.
- It does not transfer investigator responsibility. The principal investigator at each site, not the sponsor or the CRA, is accountable under FDA Form 1572 and the analogous EU CTR provisions. EOR is silent on this.
- It does not replace site contracts. Clinical trial agreements between sponsor and site, including budget, indemnification, and publication rights, sit outside any employment vehicle.
- It does not absorb sponsor pharmacovigilance obligations. Adverse-event reporting under ICH E2A and 21 CFR 312.32 stays with the sponsor.
- It does not substitute for sponsor monitoring oversight. ICH-GCP E6(R3) keeps quality accountability with the sponsor regardless of who employs the CRA.
- It does not grant clinical licensure where a CRA's role overlaps with regulated clinical activity (rare for monitoring, but worth checking in jurisdictions with restrictive scope rules).
EOR solves employment compliance. The clinical-quality system is still the sponsor's.
FAQs
Can I hire a clinical research associate in another country without opening an entity?
Yes. An Employer of Record legally employs the CRA in their home country on a locally compliant contract, while the sponsor or CRO directs the work. This is the standard route for the first several CRA hires per country.
Is it legal to engage a CRA as an independent contractor?
Rarely, for full-time CRAs. CRAs typically follow sponsor-defined monitoring plans, work fixed hours, and use sponsor systems. These patterns fail the DOL economic-realities test and parallel tests in most non-US jurisdictions. Misclassification exposes the sponsor to back-taxes, overtime, and benefits liability.
Where do most CRAs live in 2026?
Heavy concentrations in the US, UK, Poland, Spain, Portugal, Germany, Czechia, India, the Philippines, Brazil, and Mexico. The right map for any given sponsor follows its trial site footprint.
How long does it take to hire a CRA through an EOR?
Typically days to two weeks from signed MSA to local employment contract issued. Compare to three to nine months for entity setup.
Does an EOR replace ICH-GCP sponsor responsibilities?
No. ICH-GCP E6(R3) keeps sponsor responsibility for monitoring quality and oversight regardless of who is the legal employer. EOR is an employment vehicle, not a clinical-quality system.
What does a remote CRA cost loaded in Poland or Portugal?
Plan for 1.20× to 1.35× gross salary before discretionary benefits, driven by ZUS or Social Security employer contributions. Confirm with country-specific finance review.
Further reading
- Why Medical Companies are Turning to Employer of Record services
- Hiring Medical Science Liaisons Internationally
- How Medical Device Companies are Staffing Rollouts
- EOR for Biotech Startups on Tight Runway
- Global Hiring for Digital-Health and Telemedicine Companies
- How Tech Companies Are Turning to Employer of Record Services
